Prothena Corporation plc
PRTAHealthcare|Biotechnology|IE
$7.97
+0.08 (+1.01%)
DCF Value
$3.58
Tangible Book / Share
$5.23
Cash / Share
$5.28
Clinical Trials (17)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07174310 A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Parkinson's Disease | P3 | Recruiting | 900 | RCT, Double-blind | Prasinezumab, Placebo |
| NCT04777331 A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease | Parkinsons Disease | P2 | Active | 586 | RCT, Double-blind | Prasinezumab, Placebo |
| NCT03100149 A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease | Parkinson's Disease | P2 | Active | 316 | RCT, Double-blind | RO7046015, RO7046015, Placebo |
| NCT02312206 The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis | Primary Systemic (AL) Amyloidosis | P3 | Terminated | 260 | RCT, Double-blind | NEOD001 |
| NCT04973137 A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis | Light Chain (AL) Amyloidosis | P3 | Terminated | 208 | RCT, Double-blind | Birtamimab, Standard of Care Chemotherapy |
| NCT02613182 Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis | AL Amyloidosis | P2 | Terminated | 34 | Open-label | NEOD001 |
| NCT02632786 The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis | AL Amyloidosis | P2 | Completed | 129 | RCT, Double-blind | NEOD001, Placebo |
| NCT01707264 Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis | Primary Amyloidosis | P1P2 | Completed | 69 | Open-label | NEOD001 |
| NCT03154047 Study in Subjects With Light Chain (AL) Amyloidosis | AL Amyloidosis | P2 | Terminated | 80 | Open-label | NEOD001 |
| NCT06699680 Phase 1 Study of PRX019 in Healthy Adult Volunteers | Healthy Participants Study | P1 | Completed | 50 | RCT, Double-blind | PRX019, Placebo |
| NCT02630901 Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis | Psoriasis | P1 | Completed | 48 | RCT, Double-blind | PRX003 |
| NCT02458677 Single Ascending Dose Study of PRX003 in Healthy Subjects | Psoriasis | P1 | Completed | 40 | RCT, Double-blind | PRX003 |
| NCT02095171 Single Ascending Dose Study of PRX002 in Healthy Subjects | Parkinson's Disease | P1 | Completed | 40 | RCT, Double-blind | PRX002 |
| NCT03336580 A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis | Amyloidogenic Transthyretin (ATTR) Amyloidosis | P1 | Terminated | 21 | Open-label | PRX004 |
| NCT02157714 Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease | Parkinson's Disease | P1 | Completed | 64 | RCT, Double-blind | PRX002 |
| NCT03043768 Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease | Parkinson's Disease | Completed | 50 | — | — | |
| NCT02574676 Quality of Life (QOL) Registry for Patients With AL Amyloidosis | AL Amyloidosis, Amyloidosis | Completed | 343 | — | — |